Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

about

Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination.

P2860

Q36975796-5192B70F-B580-44D2-A88E-5B614B278F9D

P2860

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

Item

http://www.wikidata.org/entity/Q37125703

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

@en

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.

@nl

type

Item

label

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

@en

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.

@nl

prefLabel

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

@en

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.

@nl

P1476

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

@en

P2093

Edgar A Jaimes

http://www.w3.org/2001/XMLSchema#string

Eric Judd

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

Structure-based design of aliskiren, a novel orally effective renin inhibitor

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

P304

293-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERC.12.7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221888457

http://www.w3.org/2001/XMLSchema#string

P698

22390800

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

3754847

http://www.w3.org/2001/XMLSchema#string

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

about

P2860

P2860

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932